Intelligence / Healthtech / PMA Approvals / Ventana Medical Systems, INC. (Roche Tissue Diagnostics)
Ventana Medical Systems, INC. (Roche Tissue Diagnostics)
8 Oct 2026: Device change approved (PMA) · VENTANA MMR RxDx Panel. Recorded in the openFDA device PMA data.
- Decided
- 8 Oct 2026
- Device
- VENTANA MMR RxDx Panel
- Specialty
- Pathology
- Type
- Supplement (Normal 180 Day Track)
- Reason
- Change Design/Components/Specifications/Material
- Reference
- P210001 S016
- Location
- Tucson, AZ
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Find the decision makers at Ventana Medical Systems, INC. (Roche Tissue Diagnostics)
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Ventana Medical Systems, INC. (Roche Tissue Diagnostics) in our registers.
More in Pathology
PMA Approvals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.